LBP47: Exploring the Utility of the Digital Clock Drawing Test in Capturing Subtle Cognitive Changes and Biomarker Evidence at the Preclinical Stage of Alzheimer’s Disease
Dorene M. Rentz, PsyD1,2, Kathryn V. Papp, PhD1,2, Irina Orlovsky, MA2, William Souillard-Mandar5, Dana Penney, PhD1,2, Randall Davis, PhD1, Keith A. Johnson, MD1,2,5
(1) Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA USA (2) Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA (3) Digital Cognition Technologies, Waltham, MA USA (4) Department of Neurology, Lahey Hospital and Medical Center, Burlington, MA, USA (5) Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA

LBP48: Clinical meaningfulness of Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) scale in relation to goal attainment in participants on cholinesterase inhibitors
Susan E Howlett, PhD1,2,3, Justin Stanley, BSc1, Helen Wong, MSc1, Arnold Mitnitski, PhD1,2, Kenneth Rockwood, MD1,2
(1) DGI Clinical Inc., Halifax, NS, Canada (2) Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada (3) Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

LBP50: Assessment of iADL functioning in individuals with subjective cognitive decline using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
Alexandra S. Atkins, PhD1, Anzalee Khan PhD1, Ioan Stroescu PhD1, Kathleen A. Welsh-Bohmer PhD1, Brenda L. Plassman PhD3, Adam W. Vaughan, PhD1, Dañela Balentin, MA1 & Richard S.E. Keefe, PhD1,4
(1) NeuroCog Trials, Durham, NC, USA; (2) Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA; (3) Duke University Bryan ADRC, Durham, NC, USA; (4) Duke University Medical Center, Durham, NC, USA.